Skip to main content
. 2021 Oct 22;11:751777. doi: 10.3389/fonc.2021.751777

Figure 2.

Figure 2

OS of the patients receiving NA therapy. (A) OS comparison between the VR and non-VR groups. (B) OS comparison between the MVR and non-MVR groups. OS, overall survival; NA, nucelos(t)ide analogues.